Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P H Wilding

Showing results (1-10 of 156) with videos related to

Pageof 16
Sort By:
European Journal of Endocrinology|February 16, 2020
Endocrine testing in obesityJohn P H Wilding
Lancet (London, England)|October 9, 2019
Semaglutide in weight management - Author's replyJohn P H Wilding
Diabetologia|May 15, 2017
Medication use for the treatment of diabetes in obese individualsJohn P H Wilding
Metabolism: Clinical and Experimental|August 9, 2014
The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitorsJohn P H Wilding
BMJ (Clinical Research Ed.)|February 18, 2011
Glucagon-like peptide-1 analogues for type 2 diabetesJohn P H Wilding, Kevin Hardy
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2009
Adipokines: emerging therapeutic targetsKatarina Kos, John P H Wilding
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 18, 2020
The 1α,25(OH)<sub>2</sub>D<sub>3</sub> Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK SignalingJingjing Zhu, John P H Wilding
Nature Reviews. Endocrinology|March 3, 2010
SPARC: a key player in the pathologies associated with obesity and diabetesKatarina Kos, John P H Wilding
The Journal of Clinical Endocrinology and Metabolism|November 7, 2009
Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitusSunil Nair, John P H Wilding
Current Atherosclerosis Reports|December 26, 2023
Body Fat Depletion: the Yin Paradigm for Treating Type 2 DiabetesJingjing Zhu, John P H Wilding
Pageof 16

Showing results (1-10 of 156) with videos related to

Sort By:
Pageof 16
European Journal of Endocrinology|February 16, 2020
Endocrine testing in obesityJohn P H Wilding
Lancet (London, England)|October 9, 2019
Semaglutide in weight management - Author's replyJohn P H Wilding
Diabetologia|May 15, 2017
Medication use for the treatment of diabetes in obese individualsJohn P H Wilding
Metabolism: Clinical and Experimental|August 9, 2014
The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitorsJohn P H Wilding
BMJ (Clinical Research Ed.)|February 18, 2011
Glucagon-like peptide-1 analogues for type 2 diabetesJohn P H Wilding, Kevin Hardy
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2009
Adipokines: emerging therapeutic targetsKatarina Kos, John P H Wilding
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 18, 2020
The 1α,25(OH)<sub>2</sub>D<sub>3</sub> Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK SignalingJingjing Zhu, John P H Wilding
Nature Reviews. Endocrinology|March 3, 2010
SPARC: a key player in the pathologies associated with obesity and diabetesKatarina Kos, John P H Wilding
The Journal of Clinical Endocrinology and Metabolism|November 7, 2009
Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitusSunil Nair, John P H Wilding
Current Atherosclerosis Reports|December 26, 2023
Body Fat Depletion: the Yin Paradigm for Treating Type 2 DiabetesJingjing Zhu, John P H Wilding
Pageof 16